Five Prime Presents Data on Unique Immuno-Oncology Discovery Research at the 2017 AACR Annual Meeting
April 03 2017 - 1:00PM
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage
biotechnology company focused on discovering and developing
innovative immuno-oncology protein therapeutics, announced that a
poster featuring data related to Five Prime’s unique discovery
platform was presented today at the 2017 American Association for
Cancer Research (AACR) Annual Meeting in Washington, D.C. The
poster titled “Identification of Novel T Cell Co-Inhibitory and
Co-Stimulatory Receptors from Screening a Comprehensive Library of
Extracellular Proteins” is available at
http://www.fiveprime.com/news-media/publications-presentations.
“We have generated a comprehensive library of
essentially all human extracellular proteins and have used this
library to screen for new agents that modulate the function of
various immune cell subsets,” said Luis Borges, Ph.D., Senior Vice
President of Research at Five Prime. “Taken together, we have
developed robust in vitro and in vivo platforms that allow us to
discover new immuno-oncology targets that we believe will help
address the needs of cancer patients who fail to respond to current
immunomodulatory therapies.”
Five Prime has developed multiple sophisticated in
vitro, in vivo, and biophysical assay systems for screening its
comprehensive library of human extracellular proteins to identify
novel therapeutics that can reprogram immune cells in the tumor
microenvironment.
These multiple approaches include:
- In vitro screens of primary human effector and regulatory T
cells to identify novel proteins that can modulate T cell
activation and suppression.
- Screening subsets of the discovery library in four distinct
syngeneic mouse tumor models (either as single agents, or in
combination with checkpoint blockade or a vaccine) to identify
targets that can modulate an anti-tumor immune response in
vivo.
- Performing a combinatorial biophysical screen for extracellular
protein-protein interactions within a set of approximately 700
predicted immune-related transmembrane proteins to identify novel
receptor-ligand interaction networks.
As a result of these screens that combine data from
multiple screening approaches, Five Prime has prioritized a series
of new targets for validation and potential generation of novel
immuno-oncology therapeutics.
About Five Prime
Five Prime Therapeutics, Inc. discovers and
develops innovative therapeutics to improve the lives of patients
with serious diseases. Five Prime's comprehensive discovery
platform, which encompasses virtually every medically relevant
extracellular protein, positions it to explore pathways in cancer,
inflammation and their intersection in immuno-oncology, an area
with significant therapeutic potential and a growing focus of the
company's R&D activities. Five Prime has entered into strategic
collaborations with leading global pharmaceutical companies and has
promising product candidates in clinical and late preclinical
development. For more information, please visit
www.fiveprime.com.
Cautionary Note on Forward-looking
StatementsThis press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as "may," "will," "expect," "plan,"
"anticipate," "estimate," "intend" and similar expressions (as well
as other words or expressions referencing future events, conditions
or circumstances) are intended to identify forward-looking
statements. These forward-looking statements are based on Five
Prime's expectations and assumptions as of the date of this press
release. Each of these forward-looking statements involves risks
and uncertainties. Actual results may differ materially from these
forward-looking statements. Factors that may cause actual results
to differ from those expressed or implied in the forward-looking
statements in this press release are discussed in Five Prime's
filings with the U.S. Securities and Exchange Commission, including
the "Risk Factors" contained therein. Except as required by law,
Five Prime assumes no obligation to update any forward-looking
statements contained herein to reflect any change in expectations,
even as new information becomes available.
CONTACTS:
Heather Rowe
Investor Relations
415-365-5737
heather.rowe@fiveprime.com
Five Prime Therapeutics (NASDAQ:FPRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Five Prime Therapeutics (NASDAQ:FPRX)
Historical Stock Chart
From Sep 2023 to Sep 2024